Item 7.01 Regulation FD Disclosure.

On December 13, 2012, Auxilium Pharmaceuticals, Inc. issued a press release announcing top-line Day 30 data for XIAFLEX (collagenase clostridium histolyticum or CCH) for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with edematous fibrosclerotic panniculopathy, commonly known as cellulite.

The foregoing is qualified in its entirety by the text of the press release attached as Exhibit 99.1 hereto and incorporated herein by reference. All readers are encouraged to read the entire text of the joint press release attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. 99.1 Press Release, dated December 13, 2012, issued by Auxilium Pharmaceuticals, Inc.

---